Juana Andreo‐Lopez

Juana Andreo‐Lopez

Auto-generated profile, based on publicly available information

Juana Andreo‐Lopez

Departamento de Biologia Celular, Genetica y Fisiologia Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina‐IBIMA Plataforma BIONAND, Facultad de Ciencias, Universidad de Malaga Malaga Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2023 in British Journal of Pharmacology
Verified
Journal Article
Open access
MBMiriam Bettinetti‐Luque
Miriam Bettinetti‐Luque
LTLaura Trujillo‐Estrada
Laura Trujillo‐Estrada
EGEduardo Garcia-Fuentes
Eduardo Garcia-Fuentes
JAJuana Andreo‐Lopez
Juana Andreo‐Lopez
Raquel Sanchez-VaroRaquel Sanchez-Varo
Raquel Sanchez-Varo
DBDavid Baglietto-Vargas
David Baglietto-Vargas
Adipose tissue has recently been recognized as an important endocrine organ that plays a crucial role in energy metabolism and in the immune response in many metabolic tissues. With this regard, emerging evidence indicates that an important crosstalk exists between the adipose tissue and the brain. However, the contribution of adipose tissue to the development of age‐related diseases, including Alzheimer's disease, remains poorly defined. New studies suggest that the adipose tissue modulates brain function through a range of endogenous biologically active factors known as adipokines, which can cross the blood–brain barrier to reach the target areas in the brain or to regulate the function of the blood–brain barrier. In this review, we discuss the effects of several adipokines on the physiology of the blood–brain barrier, their contribution to the development of Alzheimer's disease and their therapeutic potential.LINKED ARTICLES: This article is part of a themed issue From Alzheimer's Disease to Vascular Dementia: Different Roads Leading to Cognitive Decline. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.6/issuetoc

13 May 2025 in Aging Cell
Verified
Journal Article
Open access
JAJuana Andreo‐Lopez
Juana Andreo‐Lopez
CNCristina Nuñez‐Diaz
Cristina Nuñez‐Diaz
KHKelly Do Huynh
Kelly Do Huynh
MNMarie Minh Thu Nguyen
Marie Minh Thu Nguyen
CCCelia Da Cunha
Celia Da Cunha
DBDavid Baglietto-Vargas
David Baglietto-Vargas
Alzheimer's disease (AD) is a complex neurodegenerative proteinopathy in which Aβ and tau misfold and aggregate into entities that structurally unsettle native proteins, mimicking a prion‐like or “seeding” process. These Aβ and tau “seeds” can arrange in different conformations or strains that might display distinct pathogenic properties. Furthermore, recent evidence suggests that microglia play a key role in the amyloidogenic event and can modulate the propagation and aggregation processes. Here, we employed histological and molecular approaches to determine whether seeds from human AD brains compared to those from transgenic mice (3xTg‐AD) are more prone to induce Aβ and tau aggregates in vivo, as well as potential differences in the microglial response to the plaque pathology. Brain homogenates were injected into the hippocampus of 3xTg‐AD mice and hAβ‐KI mice and examined at 18–20 months of age. The seeds from the human AD brain induced more aggressive amyloid pathology compared to seeds from aged 3xTg‐AD mice. However, the AD seeds from aged transgenic mice triggered more tau pathology. Interestingly, such mice seeds impaired microglial clustering around plaques, leading to more severe neuritic pathology. Furthermore, the human AD seeds injected into the hippocampus of hAβ‐KI mice were not able to induce plaque formation. These results suggest that multiple variables such as the AD seed, recipient model, and time are critical factors that can modulate the amyloid pathology onset and progression. Thus, more profound understanding of these factors will provide key insight into how amyloid and tau pathology progresses in AD.